Irritable Bowel Syndrome
- 1 January 2006
- journal article
- review article
- Published by Springer Nature in Drugs
- Vol. 66 (8) , 1073-1088
- https://doi.org/10.2165/00003495-200666080-00004
Abstract
Irritable bowel syndrome (IBS) is a highly prevalent functional gastrointestinal disorder affecting up to 3–15% of the general population in Western countries. It is characterised by unexplained...Keywords
This publication has 109 references indexed in Scilit:
- Phase III Trial of Alvimopan, a Novel, Peripherally Acting, Mu Opioid Antagonist, for Postoperative Ileus After Major Abdominal SurgeryDiseases of the Colon & Rectum, 2005
- Irritable Bowel Syndrome: Epidemiology, Natural History, Health Care Seeking and Emerging Risk FactorsGastroenterology Clinics of North America, 2005
- Corticotropin‐releasing factor 1 receptor‐mediated mechanisms inhibit colonic hypersensitivity in ratsNeurogastroenterology & Motility, 2005
- Alvimopan, a Novel, Peripherally Acting μ Opioid AntagonistAnnals of Surgery, 2004
- Treating irritable bowel syndrome: overview, perspective and future therapiesBritish Journal of Pharmacology, 2004
- Phase III efficacy and safety of RU-0211, a novel chloride channel activator, for the treatment of constipationGastroenterology, 2003
- Octreotide increases thresholds of colonic visceral perception in IBS patients without modifying muscle toneDigestive Diseases and Sciences, 1994
- U. S. Householder survey of functional gastrointestinal disordersDigestive Diseases and Sciences, 1993
- Control of muscle tone in the human colon.Gut, 1992
- Muscarinic Receptor SubtypesNew England Journal of Medicine, 1989